Drug Profile
NNC 450320
Latest Information Update: 28 Aug 2002
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Osteoporosis therapies; Pyrrolidines
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 17 Feb 1999 New profile
- 17 Feb 1999 Preclinical development for Postmenopausal osteoporosis in Denmark (PO)